DADC
ALXN

D.A. Davidson & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

D.A. Davidson & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,235
Closed -$289K – 1186
2019
Q1 		$289K Buy
+2,235
New +$278K 0.01% 897
2018
Q4 		– Sell
-1,924
Closed -$267K – 1189
2018
Q3 		$267K Buy
1,924
+29
+2% +$3.64K ﹤0.01% 957
2018
Q2 		$235K Sell
1,895
-80
-4% -$9.35K ﹤0.01% 972
2018
Q1 		$220K Hold
1,975
– – ﹤0.01% 966
2017
Q4 		$236K Sell
1,975
-181
-8% -$22K ﹤0.01% 951
2017
Q3 		$302K Buy
2,156
+15
+0.7% +$2.04K 0.01% 848
2017
Q2 		$260K Sell
2,141
-54
-2% -$6.29K 0.01% 847
2017
Q1 		$266K Sell
2,195
-692
-24% -$89.2K 0.01% 821
2016
Q4 		$351K Buy
2,887
+1,309
+83% +$160K 0.01% 777
2016
Q3 		$191K Buy
1,578
+340
+27% +$43.8K ﹤0.01% 968
2016
Q2 		$143K Buy
1,238
+220
+22% +$31.2K ﹤0.01% 971
2016
Q1 		$139K Buy
1,018
+133
+15% +$19.5K ﹤0.01% 984
2015
Q4 		$167K Hold
885
– – 0.01% 906
2015
Q3 		$137K Sell
885
-5
-0.6% -$912 ﹤0.01% 970
2015
Q2 		$159K Buy
890
+71
+9% +$12.3K 0.01% 954
2015
Q1 		$140K Sell
819
-376
-31% -$68.1K ﹤0.01% 1004
2014
Q4 		$219K Buy
1,195
+100
+9% +$18.5K 0.01% 836
2014
Q3 		$180K Buy
1,095
+725
+196% +$119K 0.01% 903
2014
Q2 		$55K Buy
370
+295
+393% +$46.6K ﹤0.01% 1378
2014
Q1 		$10K Sell
75
-13
-15% -$2.07K ﹤0.01% 1810
2013
Q4 		$10K Buy
88
+26
+42% +$3.12K ﹤0.01% 1727
2013
Q3 		$6K Buy
62
+3
+5% +$329 ﹤0.01% 1560
2013
Q2 		$4K Buy
+59
New +$5.69K ﹤0.01% 1568

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

D.A. Davidson & Co's ALXN Position: Q2 2019 in Review

D.A. Davidson & Co sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 2,235 shares — an estimated $289K sold.

D.A. Davidson & Co first reported a position in ALXN in Q2 2013 and held it in 23 quarters. The position peaked at $351K in Q4 2016. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • D.A. Davidson & Co reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • D.A. Davidson & Co sold 2,235 Alexion Pharmaceuticals shares in Q2 2019, an estimated $289K.
  • D.A. Davidson & Co first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • D.A. Davidson & Co's Alexion Pharmaceuticals position peaked at $351K in Q4 2016.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on D.A. Davidson & Co's 13F filing for Q2 2019, filed 13 Aug 2019.